CUBICIN RF Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Cubicin Rf, and when can generic versions of Cubicin Rf launch?
Cubicin Rf is a drug marketed by Cubist Pharms Llc and is included in one NDA. There is one patent protecting this drug and one Paragraph IV challenge.
This drug has forty-five patent family members in thirty-one countries.
The generic ingredient in CUBICIN RF is daptomycin. There are ten drug master file entries for this compound. Twenty-three suppliers are listed for this compound. Additional details are available on the daptomycin profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Cubicin Rf
A generic version of CUBICIN RF was approved as daptomycin by TEVA PHARMS USA on March 25th, 2016.
Summary for CUBICIN RF
International Patents: | 45 |
US Patents: | 1 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 2 |
Raw Ingredient (Bulk) Api Vendors: | 15 |
Clinical Trials: | 40 |
Patent Applications: | 3,899 |
Formulation / Manufacturing: | see details |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for CUBICIN RF |
What excipients (inactive ingredients) are in CUBICIN RF? | CUBICIN RF excipients list |
DailyMed Link: | CUBICIN RF at DailyMed |

Recent Clinical Trials for CUBICIN RF
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Vancouver Island Health Authority | Phase 4 |
McGill University Health Centre/Research Institute of the McGill University Health Centre | Phase 4 |
McGill University Health Center | Phase 4 |
Pharmacology for CUBICIN RF
Drug Class | Lipopeptide Antibacterial |
Anatomical Therapeutic Chemical (ATC) Classes for CUBICIN RF
Paragraph IV (Patent) Challenges for CUBICIN RF
Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
---|---|---|---|---|---|---|
CUBICIN RF | For Injection | daptomycin | 500 mg/vial | 021572 | 1 | 2008-11-19 |
US Patents and Regulatory Information for CUBICIN RF
CUBICIN RF is protected by one US patents.
Patents protecting CUBICIN RF
Lipopeptide compositions and related methods
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cubist Pharms Llc | CUBICIN RF | daptomycin | POWDER;INTRAVENOUS | 021572-003 | Jul 6, 2016 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | Y | See Plans and Pricing | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for CUBICIN RF
See the table below for patents covering CUBICIN RF around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Poland | 214000 | See Plans and Pricing | |
South Korea | 20070044079 | See Plans and Pricing | |
Australia | 2010321531 | Lipopeptide compositions and related methods | See Plans and Pricing |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for CUBICIN RF
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
1115417 | SPC/GB06/024 | United Kingdom | See Plans and Pricing | SUPPLEMENTARY PROTECTION CERTIFICATE NO SPC/GB06/024 GRANTED TO CUBIST PHARMACEUTICALS, INC IN RESPECT OF THE PRODUCT DAPTOMYCIN, THE GRANT OF WHICH WAS ADVERTISED IN JOURNAL NO 6162 DATED 27 JUNE 2007 HAS HAD ITS MAXIMUM PERIOD OF DURATION CORRECTED, SUBJECT TO THE PAYMENT OF THE PRESCRIBED FEES IT WILL EXPIRE ON 22 JANUARY 2021. |
1115417 | 22/2006 | Austria | See Plans and Pricing | PRODUCT NAME: DAPTOMYCIN; REGISTRATION NO/DATE: EU/1/05/328/001 UND 002 20060119 |
1115417 | CA 2006 00018 | Denmark | See Plans and Pricing | PRODUCT NAME: DAPTOMYCIN |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |